Prolonged therapy for Hepatitis C with Low-Dose Peginterferon

New England Journal of Medicine

Volumn 360, Issue 11, 2009, Pages 1151-1153

  Koretz, Ronald L ^a   Gluud, Christian ^a  

^a Cochrane Hepato Biliary Group ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON;

COST; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; PRIORITY JOURNAL; ANTIVIRAL THERAPY; BIOPSY; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; OUTCOME ASSESSMENT; TREATMENT OUTCOME; VIROLOGY;

EID: 62349099152     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc082747     Document Type: Letter

References (4)

1. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginter feron. N Engl J Med 2008;359:2429-41.
2. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007;46:734-42.
3. Koretz RL. Decisions, decisions, decisions. Gastroenterology 2000;118:1268-70.
4. Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403. [Erratum, Ann Intern Med 2008; 149:844.]